LIM Kinase (LIMK)
LIMKs
LIM kinases (LIMKs) are important cell cytoskeleton regulators that play a prominent role in cancer manifestation and neuronal diseases. The LIMK family consists of two homologues, LIMK1 and LIMK2, which differ from one another in expression profile, intercellular localization, and function. The main substrate of LIMK is cofilin, a member of the actin-depolymerizing factor (ADF) protein family. When phosphorylated by LIMK, cofilin is inactive. LIMKs play a contributory role in several neurodevelopmental disorders and in cancer growth and metastasis.
LIM domain kinases (LIMK1 and 2) are substrate for Cdc42/Rac-PAK, and modulate actin dynamics by phosphorylating cofilin at serine-3. This modification inactivates cofilin’s actin severing and depolymerizing activity. LIMKs also translocate into the nucleus and regulate cell cycle progression. LIMKs are potential therapeutic targets for NF2 and other merlin-deficient tumors.
LIM Kinase (LIMK) Isoform Specific Products
All Product Categories
-
LIM Kinase (LIMK) Related Products (48)
Related Products (48)
-
Antibodies (4)
-
LIM Kinase (LIMK) Isoform Comparison
-
LIMK1-IN-3
0 ImagesCat. No.: HY-W150222CAS No.: 4994-89-2LIMK1-IN-3 is a LIMK1 inhibitor with an IC50 of 4.4 μM. LIMK1-IN-3 shows potential for use in cancer-related research.
-
Aurora/LIM kinase-IN-1
0 ImagesCat. No.: HY-144438Aurora/LIM kinase-IN-1 (Compound F114) is a potent and dual inhibitor of aurora and lim kinase. Aurora kinases and lim kinases are involved in neoplastic cell division and cell motility, respectively. Aurora/LIM kinase-IN-1 inhibits GBM proliferation and invasion. Aurora/LIM kinase-IN-1 is a promising new scaffold for dual aurora/lim kinase inhibitors that may be used in future agent development efforts for GBM, and potentially other cancers.
-
S3 peptide TFA
0 ImagesCat. No.: HY-P12114Purity: 98.19%S3 peptide is a multifunctional synthetic peptide that acts as a LIMK1 inhibitor with an IC50 of 40 μg/mL. S3 peptide blocks cofilin phosphorylation and SDF-1α (HY-P4911)-induced T cell chemotaxis, and reduces viral particle production of HIV-1 and M-PMV. S3 peptide forms dimers via intermolecular disulfide bonds to bind and disrupt LPS micelles, exerting anti-Gram-negative bacterial activity. S3 peptide serves as a targeting moiety for NKA α1 and is used for the construction of PET tracers. S3 peptide is applicable to research related to HIV-1 infection, M-PMV infection, breast cancer, liver cancer and non-small cell lung cancer.
-
LIMK1 inhibitor 1
0 ImagesCat. No.: HY-169605CAS No.: 332904-10-6LIMK1 inhibitor 1 (compound 24) is a LIMK1 inhibitor. LIMK1 inhibitor 1 can be used in anti-cancer research.
-
CZh226
0 ImagesCat. No.: HY-111103CAS No.: 2196199-00-3CZh226 is a selective PAK4 inhibitor with an IC50 of 0.0111 μM and a Ki of 0.009 μM. CZh226 functionally inhibits PAK4 activity and reduces the phosphorylation level of downstream signaling molecules. CZh226 inhibits the migration and invasion of tumor cells. CZh226 is applicable to lung cancer-related research.
-
LX7101 monohydrochloride
0 ImagesCat. No.: HY-12659BCAS No.: 2319882-48-7LX7101 monohydrochloride is a potent LIM-kinase, ROCK and PKA inhibitor with IC50s of 24 nM, 1.6 nM, 10 nM and <1 nM for LIMK1, LIMK2, ROCK2 and PKA, respectively. LX7101 monohydrochloride proves significantly selective for LIMK2 with IC50 values of 4.3 nM and 32 nM for LIMK2 and LIMK1 at 2 μM ATP, respectively. LX7101 monohydrochloride has the potential for ocular hypertension and associated glaucoma research.
